PPG introduces PPG LINQ Color software and PPG MAGICBOX body shop assistant for the refinish industry
30.8.2023 16:00:00 EEST | Business Wire | Press release
PPG (NYSE: PPG) today announced the introduction of PPG LINQ™ Color software and the PPG MAGICBOX™ body shop assistant for smarter wireless mixing in automotive repair shops. The advanced tools are the latest components of the PPG LINQ end-to-end digital solution for the global refinish industry that provide productivity and sustainability improvement for body shops.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830721690/en/
The PPG MAGICBOX™ smart device eliminates the need for specialized computers in the mixing room by delivering a PPG patented body shop assistant, connectable to new and existing USB scales in body shops. (Photo: Business Wire)
With PPG LINQ, refinish customers can streamline their repair process by using PPG’s cloud-based platform and its interconnected digital hardware, software and related services. The PPG MagicBox body shop assistant is a small but powerful device that communicates environmental conditions in mixing rooms and receives formulas direct from the PPG LINQ Color software. These new tools also extend the digital ecosystem to smaller body shops not previously served by the PPG LINQ solution.
The PPG LINQ system delivers benefits including faster color-matching from any internet-connected device; less rework and no need for spray-out cards; faster and more efficient paint mixing; and waste reduction, when compared to a traditional repair process.
“When our PPG LINQ digital ecosystem is paired with our industry-leading paint products, we can help body shop owners to realize a 15% ‘key-to-key’ productivity improvement,” said Chancey Hagerty, PPG senior vice president, Automotive Refinish. “From the time a customer leaves their key with a body shop until they return to collect their car, that body shop can achieve improved productivity, reduced waste and enhanced sustainability compared to a traditional repair approach.”
The launch of PPG LINQ Color software and the PPG MagicBox body shop assistant follows the launch of other PPG LINQ digital ecosystem products, including PPG VISUALIZID™ software, the PPG DIGIMATCH™ spectrophotometer and the PPG MOONWALK® system, the company’s award-winning, automated paint mixing system launched in 2019.
“Today, thousands of body shops around the globe already use the PPG MoonWalk, PPG VisualizID and PPG DigiMatch tools,” said Alban d’Epenoux, PPG global marketing director, Automotive Refinish. “The addition of PPG LINQ Color software and the PPG MagicBox device can also mean additional productivity and enhanced capabilities for those existing users and also for thousands of other body shops interested in adopting the best digital solutions to enhance their business performance.”
To learn more about the PPG LINQ digital solution, visit https://ppglinq.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG LINQ, MagicBox, Digimatch, and VisualizID are trademarks, and MoonWalk, the PPG Logo and We Protect and Beautify the World are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Automotive Refinish
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830721690/en/
Contact information
Michelle Deemer
Automotive Refinish
+1 412 728 0195
mdeemer@ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
